Octagon Capital Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Octagon Capital Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-530,000	Closed	-$27.9M	–	32
2026 Q1	$27.9M	Buy	+530,000	New	+$21.8M	3.09%	14
2024 Q3	–	Sell	-1,364,400	Closed	-$9.29M	–	51
2024 Q2	$9.29M	Buy	1,364,400 +739,400	+118%	+$4.48M	1.46%	19
2024 Q1	$4.1M	Buy	+625,000	New	+$4.08M	0.49%	40

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Octagon Capital Advisors's TERN Position: Q2 2026 in Review

Octagon Capital Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 530,000 shares — an estimated $27.9M sold.

Octagon Capital Advisors first reported a position in TERN in Q1 2024 and held it in 3 quarters. The position peaked at $27.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Octagon Capital Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Octagon Capital Advisors sold 530,000 Terns Pharmaceuticals shares in Q2 2026, an estimated $27.9M.
Octagon Capital Advisors first reported a position in Terns Pharmaceuticals in Q1 2024 and held it in 3 quarters.
Octagon Capital Advisors's Terns Pharmaceuticals position peaked at $27.9M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.